ArticleNPJ vaccines2022
Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination.
Article in NPJ vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- An overview and single-arm meta-analysis of immune-mediated adverse events following COVID-19 vaccination.Frontiers in pharmacology · 2024Pooled it
- Vaccinology in the twenty-first century revisited.NPJ vaccines · 2026Article
- Article
- Serious adverse drug reactions associated with anti-SARS-CoV-2 vaccines and their reporting trends in the EudraVigilance database.Scientific reports · 2025Observational
- Disproportionality Analysis of the Five Most Widespread Neurological Effects of COVID-19 Vaccines from 2021 to 2023: Insights from EudraVigilance.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2.Vaccines · 2025Review
- Development of a novel adenovirus type 4 vector as a promising respiratory vaccine vehicle.Frontiers in immunology · 2025Article
- The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury.Advances in virology · 2025Review
- Factors Predicting COVID-19 Vaccine Effectiveness and Longevity of Humoral Immune Responses.Vaccines · 2024Review
- Review
- Incidence and management of the main serious adverse events reported after COVID-19 vaccination.Pharmacology research & perspectives · 2024Review
- Article
- Messenger RNA Vaccine Technology: Success for SARS-CoV-2 and Prospects for an HIV-1 Vaccine.Topics in antiviral medicine · 2024Review
- A solution towards a viable compensation mechanism for injury from COVID-19 vaccines in Malaysia: A qualitative study.Heliyon · 2024Article
- Article
- Deciphering deaths associated with severe serious adverse events following SARS-CoV-2 vaccination: A retrospective cohort study.Vaccine: X · 2024Article
- Article
- Differences and similarities between COVID-19 related-headache and COVID-19 vaccine related-headache. A case-control study.Revista de neurologia · 2023Article
- Cerebral venous sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia in middle-income countries.International journal of stroke : official journal of the International Stroke Society · 2023Article
- 'Spikeopathy': COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.